Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas - Concepedia

Concepedia

Publication | Open Access

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas

DOI Full Paper Access

128

Citations

30

References

2016

Year

Jaishri O. Blakeley, Xiaobu Ye, Dan G. Duda, Chris Halpin, Amanda L. Bergner, Alona Muzikansky, Vanessa L. Merker, Elizabeth R. Gerstner, Laura M. Fayad, Shivani Ahlawat,

Journal of Clinical Oncology

Abstract

Bevacizumab treatment resulted in durable hearing response in 36% of patients with NF2 and confirmed progressive VS-associated hearing loss. Imaging and plasma biomarkers showed promising associations with response that should be validated in larger studies.

References

	Year	Citations

Page 1